Stories about science-based entrepreneurship
Join us at this From Lab to Market x Health Talks event to discover three different stories, around all living things! This time we’re hearing developments from researchers in health and life sciences, turning research into innovations to solve real life problems!
How to create impact out of research? How to turn your research into action? Could I, should I, commercialize my research? Do I have to leave academia, can I ever return? What does science-based entrepreneurship or academic entrepreneurship mean?
These questions among many others related to the area of research to impact are being pondered by many researchers and academics. Now you’ll have a chance to exchange thoughts over a cup of coffee on how to create impact from research and network across disciplines and organizations!
Meet the speakers
Dr. Edward Hæggström is one of the co-founders of Nanoform, an innovative nanoparticle medicine enabling company. Additionally, he has been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. Previously he has held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University, and project leader at the CERN. He has a Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology. Dr. Hæggström is a scientific advisor and the Chairman of the Board of Directors of GlucoModicum Oy.
Sara Feola is a Postdoctoral Researcher in Pharmaceutical Biosciences at Helsinki University. She obtained her Ph.D. from the University of Naples Federico II and she has been working with ImmunoViroTherapy (IVTLab at University of Helsinki) since the beginning of 2016. After defending her Ph.D. thesis in the spring of 2018, she started working as a postdoctoral researcher at the IVTLab and is involved in the identification of tumor antigens using a state-of-art immunoaffinity purification-based method. Additionally, she is developing a novel method named PeptiCHIP for the isolation of tumor antigens from scarce biological material. The final aim is the generation of a personalized cancer vaccine, coating oncolytic viruses with peptides to stimulate both de-novo and pre-existing immune response.
Sakari Nikinmaa is a researcher and a medical technology executive with a Biomedical Engineering and Industrial management background with years of hands-on experience. He has successfully generated and commercialized new technology for Finland as an innovation fellow in the first Biodesign Finland project, as Lead engineer in the successful TUTL-project and as the CEO and Co-founder of Koite Health Oy. Sakari is an inventor in 5 patent applications and has successfully built up and led ISO13485 and ISO9001 quality systems and multiple medical device approvals.
Follow the event updates on our Facebook and Linkedin events.
The From Lab to Market event series is organized by Aalto Ventures Program, VTT Launchpad, Aalto Startup Center and Aalto Innovation Services in collaboration with Health Talks and Helsinki Institute of Life Sciences (HiLIFE). FLTM events are supported by Helsinki Think Company.
